Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 9/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7910007 | 0.91 | MEN1 (0.50) | MEN1KMT2AHCAR3L3MBTL1PKM | |
| SCHEMBL6559027 | 0.83 | ATM (0.49) | MEN1KMT2AHCAR3ALDH1A1KDM4E | |
| SCHEMBL6559021 | 0.83 | ATM (0.49) | MEN1KMT2AHCAR3ALDH1A1KDM4E | |
| SCHEMBL14735881 | 0.81 | HCAR3 (0.57) | MEN1KMT2AHCAR3TSHRCASP6 | |
| SCHEMBL6560128 | 0.81 | HCAR3 (0.57) | MEN1KMT2AHCAR3TSHRCASP6 | |
| SCHEMBL6560138 | 0.81 | HCAR3 (0.57) | MEN1KMT2AHCAR3TSHRCASP6 | |
| SCHEMBL6560146 | 0.81 | HCAR3 (0.57) | MEN1KMT2AHCAR3TSHRCASP6 | |
| SCHEMBL7922373 | 0.78 | KMT2A (0.49) | MEN1KMT2AHCAR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL29276459 | 0.77 | HCAR3 (0.52) | MEN1KMT2AHCAR3TSHRCASP6 | |
| SCHEMBL7596223 | 0.76 | HCAR3 (0.53) | MEN1KMT2AHCAR3ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6211177-B1 | SIDE EFFECT REDUCTION | CELL PATHWAYS, INC. | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | MEN1 1677/4885KMT2A 1590/4885HCAR3 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.